期刊文献+

9401对H22肝癌小鼠放射增敏效应的研究 被引量:1

Radiosensitizing effects of 9401 on mice bearing H22 hepatoma
原文传递
导出
摘要 目的探讨9401对H22肝癌小鼠的放射增敏作用。方法建立H22肝癌小鼠模型,按照给药和照射的不同,分为空白对照组、单纯照射组、烟酰胺联合照射组、9401高剂量联合照射组、9401中剂量联合照射组和9401低剂量联合照射组。照射后观察H22肝癌小鼠的肿瘤生长情况、记录肿瘤照射后的生长时间,并计算肿瘤生长的延迟时问和各组的放射增敏系数。照射后28d处死小鼠,剥瘤称重,计算抑瘤率。结果9401高、中、低各剂量联合照射组均能延缓肿瘤生长,其中9401高、中剂量联合照射组与烟酰胺联合照射组相比,差异有统计学意义(t=24.7和7.5,P均〈0.01),且9401高、中剂量组辐射敏感性均显著增高,增敏系数分别为2.13、1.73,明显高于烟酰胺联合照射组的增敏系数1.61,差异有统计学意义(江2.26和9.04,P均〈0.05);9401高、中、低各剂量联合照射组的抑瘤率分别为64.5%、50.9%、42.6%,烟酰胺联合照射组的抑瘤率为53.2%,9401高剂量组抑瘤效果显著高于烟酰胺联合照射组,差异有统计学意义(t=2.8,P〈0.05)。9401高、中、低各剂量组与单纯照射组相比,抑瘤率差异有统计学意义(t=5.7,4.0和2.2,P均〈0.05)。结论9401对H22肝癌小鼠肿瘤生长有明显的抑制作用,抑制肿瘤作用随给药剂量的增加而逐步增强,放射增敏效果显著,临床应用前景广阔。 Objective To investigate the radiosensitizing effects of 9401 on mice bearing H22 hepatoma. Methods Mouse model bearing H22 hepatoma cells were established. Mice were randomly divided into six groups, the control group, the radiation group and four treatment groups including 9401 at high, medium and low dosages and nicotinamide combined with radiation. After irradiated, the growth of tumor was observed, the time of tumor growth was recorded, the delay time of tumor growth and enhancement factor (EF)were calculated. After 28 days, the mice were killed, the tumors were stripped and inhibition rate was calculated. Results Groups of 9401 combined with radiation could pestpone tumor growth. The difference was statistically significant between 9401 groups at high, medium dosages combined with radiation and nicotinamide combined with radiation group (t=24.7 and 7.5, both P〈0.01 ). Compared with radiation alone group, groups of 9401 combined with radiation had significant radiosensitizing effect. The enhancement factor of 9401 combined with radiation groups at high and medium dosages were 2.13 and 1.73 respectively, they were significant higher than nicotinamide combined with radiation group (t=2.26 and 9.04, both P〈 0.05 ). The inhibition rate of 9401 groups at high, medium and low dosages combined with radiation were 64.5%, 50.9% and 42.6% respectively. The inhibition rate of nicotinamide group combined radiation was 53.2%. The inhibition rate of 9401 at high dosage combined with radiation had significant difference with nicotinamide combined radiation (t =2.8, P〈0.05). Nicotinamide combined with radiation group, 9401 combined with radiation groups could significant inhibit the growth of tumors compared with radiation alone group (t=5.7, 4.0 and 2.2, all P〈0.05). Conclusion 9401 can inhibit the tumor growth and the inhibition effect increases gradually with the drug dose increasing. It also has radiosensitizing effects on mice bearing H22 hepatoma and present broadly clinical practice prospect.
出处 《国际放射医学核医学杂志》 2013年第1期13-15,37,共4页 International Journal of Radiation Medicine and Nuclear Medicine
基金 天津市科技计划项目(09ZCKFSH01500)
关键词 肝肿瘤 辐射增敏剂 剂量效应关系 药物 模型 动物 小鼠 Hepatoma Radiation-sensitizing agents Dose-response relationship, drug Model, animal Mice
  • 相关文献

参考文献10

  • 1顾菲,刘晓秋,韩英,赵艳芝,胡晓林,宋汝亮.肿瘤放疗增敏药9401号的细胞毒性和体外放射增敏作用[J].中国辐射卫生,2006,15(4):392-393. 被引量:7
  • 2赵阿津,刘晓秋,韩英.9401号药对小鼠皮肤放射反应试验[J].中国药理通讯,2009,26(2):79-79. 被引量:3
  • 3叶因涛,徐文清,沈秀,仲巍,杨娜.二氢丹参酮Ⅰ对H22肝癌荷瘤小鼠的放射增敏作用[J].中国辐射卫生,2009,18(3):284-285. 被引量:7
  • 4Milas L,Fujii T,Hunter N. Enhancement of tumor radioresponse in vivo by gemcitabine[J].Cancer Research,1999,(01):107-114.
  • 5Fenton BM,Lord EM,Paoni SF. Enhancement of tumor perfusion and oxygenation by carbogen and nicotinamide during singleand multifraction irradiation[J].Radiation Research,2000,(01):75-83.doi:10.1667/0033-7587(2000)153[0075:EOTPAO]2.0.CO;2.
  • 6Bussink J,Kaanders JH,Rijken PF. Vascular architecture anmicroenvironmental parameters in human squamous cell carcinomaxenografts:effects of carbogen and nicotinamide[J].Radiotherapy and Oncology,1999,(02):173-184.doi:10.1016/S0167-8140(99)00010-9.
  • 7Bussink J,Kaanders JH,Van der Kogel AJ. Clinical outcome and tumour microenvironmental effects of accelerated radiotherapy with carbogen and nicotinamide[J].Acta Oncologica,1999,(07):875-882.
  • 8Nishioka A,Ohizumi Y,Lam GK. The effects of nicotinamide plus carbogen or pions for microscopic SCCVII tumors[J].Oncology Reports,1999,(03):583-586.
  • 9Kaanders JH,Bussink J,Van der Kogel AT. ARCON:a novel biology-based approach in radiotherapy[J].Lancet Oncology,2002,(12):728-737.doi:10.1016/S1470-2045(02)00929-4.
  • 10Kaanders JH,Pop LA. Accelerated radiotherapy with carbogen and nicotinamide (ARCON) for laryngeal cancer[J].Radiotherapy and Oncology,1998,(02):115-122.

二级参考文献9

共引文献11

同被引文献12

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部